| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1,129.0 | 1,084.0 |
| Gross profit | 830.0 | 733.0 |
| Profit before tax | 264.0 | 220.0 |
| Net income | 220.0 | 150.0 |
| EPS (diluted, $ a share) | $1.43 | $0.98 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +46.7% |
|---|---|
| Revenue, year on year | +4.2% |
| Gross margin | 73.5% |
| Operating margin | 27.0% |
10-Q filed with the SEC, NASDAQ: ILMN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Illumina, Inc.: key numbers
- Share price
- $198.00Close, Nov 16
- Market cap
- $29.9B
- Shares outstanding
- 151.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Illumina, Inc.
All →Illumina Director Keith A. Meister Sells $61.1M of Stock
Keith A. Meister, Director, sold 280,091 shares of Illumina, Inc. at $212.97 to $222.44 a share (average $218.12) in 21 transactions, worth $61.1M in total between Nov 9, 2026 and Nov 11, 2026. Shares held after the trade: 208,826 (-0.9%).
- Value
- $61.1M
- Shares
- 280,091
- Average price
- $218.12
- Role
- Director
- Holding change
- -0.9%
- Trade date
- Nov 9, 2026 to Nov 11, 2026
Illumina VP, CAO Scott D. Ericksen Sells $58.1K of Stock
Scott D. Ericksen, VP, CAO, sold 267 shares of Illumina, Inc. at $217.76 a share, worth $58.1K in total on Nov 10, 2026. Shares held after the trade: 14,029 (-1.9%).
- Value
- $58.1K
- Shares
- 267
- Price
- $217.76
- Role
- VP, CAO
- Holding change
- -1.9%
- Trade date
- Nov 10, 2026
Illumina Director Keith A. Meister Sells $66.6M of Stock
Keith A. Meister, Director, sold 281,433 shares of Illumina, Inc. at $225.12 to $241.42 a share (average $236.50) in 13 transactions, worth $66.6M in total between Nov 3, 2026 and Nov 4, 2026. Shares held after the trade: 488,917 (-0.1%).
- Value
- $66.6M
- Shares
- 281,433
- Average price
- $236.50
- Role
- Director
- Holding change
- -0.1%
- Trade date
- Nov 3, 2026 to Nov 4, 2026
Illumina Financial Results
Illumina reported Q3 2026 revenue of $1.13 billion, up 4.2% year-over-year, driven by healthy clinical demand and robust NovaSeq X placements. Based on this momentum, the company raised its full-year 2026 revenue guidance to $4.64-$4.66 billion and non-GAAP EPS guidance to $5.40-$5.45.
“In the third quarter, healthy clinical demand and robust NovaSeq X placements drove results above our guidance. Based on continued momentum, we are raising our full year revenue and earnings guidance.”
Jacob Thaysen, Chief Executive Officer of Illumina
“As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem. Together with our customers, we are laying the foundation for AI to transform our understanding of human biology and improve patient outcomes.”
Jacob Thaysen, Chief Executive Officer of Illumina
Illumina $1B Debt Financing
Illumina, Inc. established a new $1.0 billion unsecured commercial paper program to issue short-term notes for general corporate purposes. The notes will have maturities of up to 397 days and will be issued through three commercial paper dealers. As of the filing date, no notes were outstanding under the program.
- Value
- $1B
- Term
- up to 397 days